Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2026年第二次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2026 second extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and validation of the meeting's legality and voting results. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a legal opinion on a shareholders' meeting. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal procedural filing related to corporate governance and shareholder meetings, but not a direct governance report or voting result declaration. The document length is about 3,000 characters, which is short and focused on legal opinion rather than a full report. Therefore, the classification is RNS with high confidence.
2026-04-27 Chinese
2025年度独立董事述职报告（程志鹏）
Board/Management Information Classification · 95% confidence The document is titled '2025年度独立董事述职报告（程志鹏）' which translates to '2025 Annual Independent Director's Work Report (Cheng Zhipeng)'. It is a detailed report by an independent director about his duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings, committee participation, communication with auditors, and protection of minority shareholders' rights. It is a comprehensive management-related report focusing on governance and director duties rather than financial results or audit opinions. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is not a simple announcement or voting result. The document fits best under Board/Management Information (MANG) as it relates to the independent director's report on his management and board activities for the year.
2026-04-27 Chinese
2025年度独立董事述职报告（黄元林）
Board/Management Information Classification · 95% confidence The document is titled '2025年度独立董事述职报告（黄元林）' which translates to '2025 Annual Independent Director's Work Report (Huang Yuanlin)'. It is a detailed report by an independent director about his duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings, committee participation, communication with shareholders, and compliance with governance regulations. It is not an announcement of a report publication, nor a financial report like an annual or interim report. It is also not a regulatory filing or certification. The document focuses on the independent director's management and governance role, which fits best under Board/Management Information (MANG). The length is over 5,000 characters and contains substantive content about management and board activities, not just a brief announcement or proxy material.
2026-04-27 Chinese
关于召开2025年年度股东会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Sichuan Zitigong Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, registration procedures, and proxy authorization forms. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the upcoming AGM. The presence of agenda items such as the 2025 annual report and other reports to be voted on confirms this is an AGM notice. The document length is 3607 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-04-27 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Annual Internal Control Evaluation Report'. It is issued by the company's board and discusses the internal control evaluation for the fiscal year ending December 31, 2025. The content includes detailed descriptions of internal control environment, risk assessment, control activities, and evaluation conclusions. It is a comprehensive report on the company's internal control system effectiveness and compliance with relevant laws and regulations. This type of document is a standalone audit-related report focusing on internal control evaluation, not a full annual report or financial statement. It does not announce voting results, management changes, or earnings, nor is it a presentation or a regulatory filing of a different nature. Therefore, the most appropriate classification is 'Audit Report / Information (AR)'. The document length (over 10,000 characters) and detailed substantive content confirm it is the report itself, not just an announcement. FY 2025
2026-04-27 Chinese
关于2026年董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 100% confidence The document is an announcement regarding the 2026 remuneration scheme for the company's directors and senior management. It details the salary structure, applicable personnel, and approval process by the board and committees. There is no financial data, audit information, or report attached. The content focuses on compensation policies for executives and directors, which fits the definition of Remuneration Information filings. The document length is short (1549 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2026-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.